Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

8:37 AM ET 8-K
Clinical Trial Data Aptevo Therapeutics Inc. APVO

Aptevo Therapeutics Clinical Trial Data

Aptevo Therapeutics announced a clinical milestone for mipletamig in frontline AML, achieving a substantial reduction in infusion-related reactions (IRRs) through a refined priming-dose regimen. This optimization, identified through FDA discussions, improves patient tolerability in the ongoing RAINIER study as the company prepares for Phase 2 development.

“We have made substantial progress in improving mipletamig’s tolerability for patients with frontline AML. Mipletamig has demonstrated a differentiated safety and tolerability profile, and successive refinements to the priming-dose regimen have substantially reduced the occurrence of infusion-related reactions. Reducing these reactions matters to patients: it has the potential to make treatment easier to tolerate and limit complications that can disrupt care. These findings are an important part of our preparations for the next stage of clinical development.”

Dirk Huebner, M.D., Chief Medical Officer of Aptevo Therapeutics
8:33 AM ET 8-K
M&A Deal Atii Holdings Inc. NANO

Forge Nano Holdings M&A Deal with HZO, Inc.

Forge Nano Holdings, Inc. has completed the acquisition of HZO, Inc., a provider of protective nanocoatings for electronics. The deal combines Forge Nano's Atomic Layer Deposition (ALD) platform with HZO's high-volume Parylene and thin-film coating business and global customer base. The acquisition is intended to provide customers with a single surface engineering partner across the device lifecycle, from wafers to finished assemblies.

Counterparty
HZO, Inc.

“HZO has spent more than a decade solving a problem every electronics manufacturer has and few can solve at scale: protecting devices from the environments they live in. Their Parylene platform, their customer relationships and their production discipline are exactly what we need as our ALD technology moves from the lab to high-volume manufacturing. We are pleased to welcome the HZO team to Forge Nano.”

Paul Lichty, Chief Executive Officer of Forge Nano

“Forge Nano and HZO were built on the same conviction, that the most valuable engineering in a modern device often happens in a layer too thin to see. HZO learned how to deliver that engineering at production volume for some of the most demanding customers in the world. Forge Nano brings the atomic-scale science, the public-company platform and the capital to take it much further. Our customers will see one partner with a wider toolkit, and our people will see a company whose ambition matches th”

Rachael Lerebours, President of HZO
8:33 AM ET 8-K
M&A Deal First Capital Inc FCAP

First Capital Signs $33.2M M&A Deal with First Bancorp of Indiana, Inc.

First Capital, Inc. (FCAP) has entered into a definitive agreement to acquire First Bancorp of Indiana, Inc. (FBPI) in an all-stock transaction valued at approximately $33.2 million. First Bancorp shareholders will receive 0.3075 shares of First Capital common stock for each share held, expanding First Capital's banking presence in Southern Indiana and Western Kentucky.

Value
$33.2M
Counterparty
First Bancorp of Indiana, Inc.

“We are extremely excited to partner with First Bancorp and further expand our presence across Southern Indiana and Western Kentucky. The expansion of our branch network across these markets will allow us to attract additional talent, build meaningful customer relationships and grow our franchise through a partnership with an organization that shares our approach to community banking.”

Chris Frederick, President and Chief Executive Officer of First Capital

“We are pleased to join First Capital’s strong franchise and believe the cultural alignment between our organizations is ideal for the next chapter for First Bancorp’s customers, employees and shareholders.”

Michael Head, President and Chief Executive Officer of First Bancorp
8:32 AM ET 8-K
Regulatory Approval Mmex Resources Corp MMEX

Mmex Resources Regulatory Approval

MMEX Resources' affiliate received approval from the Texas Commission on Environmental Quality (TCEQ) for its UltraClean Refinery North facility in Pecos County. This approval, combined with a previous approval for the South facility, enables a planned refinery complex with a processing capacity of 60,000 barrels of crude oil per day.

Counterparty
Texas Commission on Environmental Quality
8:07 AM ET 8-K
Capital Raise Avalo Therapeutics, Inc. AVTX

Avalo Therapeutics Capital Raise

Avalo Therapeutics entered into an at-the-market (ATM) sales agreement with Jefferies LLC to establish a program for the potential issuance and sale of up to $200 million of common stock. Simultaneously, the company terminated its existing sales agreement with TD Securities (USA) LLC (formerly TD Cowen) that had been in place since June 2025.

Counterparty
Jefferies LLC
8:03 AM ET 8-K
M&A Deal Lifecore Biomedical, Inc. \De\ LFCR

Lifecore Biomedical, Inc. \De\ M&A Deal with Lifecore Inc.

Lifecore Biomedical announced that the Department of Justice and the Federal Trade Commission granted early termination of the HSR Act waiting period for its pending merger with Lifecore Inc. This satisfies a key regulatory closing condition for the transaction, which remains subject to stockholder approval and other customary conditions. Lifecore Biomedical will become a wholly owned subsidiary of Lifecore Inc. upon completion of the deal.

Counterparty
Lifecore Inc.
7:59 AM ET 8-K
Capital Raise 3D Systems Corp DDD

3D Systems Capital Raise

3D Systems Corporation entered into a Sales Agreement with Cantor Fitzgerald & Co. to establish an at-the-market (ATM) offering program for up to $42.5 million of its common stock. The company is not obligated to sell any shares and may suspend or terminate the program at any time. Cantor Fitzgerald will receive a commission of up to 3.0% of the gross sales price for any shares sold.

Counterparty
Cantor Fitzgerald & Co.
7:20 AM ET 8-K
M&A Deal Black Spade Acquisition III Co BIII

Black Spade Acquisition III M&A Deal with Astrum Space Inc

Black Spade Acquisition III Co entered into a first amendment to its existing business combination agreement with Astrum Space Inc. The amendment updates the terms to allow the surviving company to list on either the NYSE or Nasdaq, as mutually agreed upon by both parties. This filing provides a status update on the pending merger between the SPAC and the satellite-to-device network company.

Counterparty
Astrum Space Inc
7:16 AM ET 8-K/A
Divestiture TripAdvisor, Inc. TRIP

TripAdvisor Divestiture to American Express Travel Related Services Company, Inc. for $700M

Tripadvisor completed the sale of its European online restaurant reservation platform, TheFork, to American Express Travel Related Services Company for $700 million in cash. The transaction closed on November 1, 2026, following the receipt of required regulatory approvals and completion of employee consultation processes. This filing provides the required pro forma financial information reflecting the business as a discontinued operation.

Value
$700M
Counterparty
American Express Travel Related Services Company, Inc.
7:09 AM ET 8-K
Divestiture DTE Energy Co DTE

DTE Energy Divestiture to Velocity BidCo LLC for $2.97B

DTE Energy Company entered into a definitive agreement to sell its wholly owned subsidiary, DTE Energy Resources, LLC (d/b/a DTE Vantage), to Velocity BidCo LLC for approximately $2.97 billion. DTE Vantage operates renewable energy projects and custom energy solutions for industrial and commercial customers. The transaction is expected to close no earlier than December 31, 2026, subject to regulatory approvals including HSR and FERC authorization.

Value
$2.97B
Counterparty
Velocity BidCo LLC
7:08 AM ET 8-K
Clinical Trial Data Precision Biosciences Inc DTIL

Precision Biosciences Clinical Trial Data

Precision BioSciences announced successful Phase 1 results for PBGENE-HBV in chronic hepatitis B, showing 100% pgRNA loss to undetectable levels at the 0.4 mg/kg dose and evidence of cccDNA elimination. The company also reported that the first patient dosed with PBGENE-DMD for Duchenne muscular dystrophy completed an eight-week safety observation period with no serious adverse events, allowing the Phase 1/2 trial to proceed with additional dosing.

7:08 AM ET 8-K
Clinical Trial Data Genprex, Inc. GNPX

Genprex Clinical Trial Data

Genprex announced translational analysis results from 11 lung cancer patients treated with its lead gene therapy candidate, Reqorsa (quaratusugene ozeplasmid). The data, presented at the GSA 2026 Annual Scientific Meeting, showed that Reqorsa administration triggers a transcriptional shift toward cellular maintenance, mitochondrial adaptation, and autophagy by 24 hours post-treatment. These findings suggest the TUSC2 gene delivered by Reqorsa enhances cellular resilience to aging-associated stress and deepens the company's understanding of the drug's biological impact.

Counterparty
Meharry Medical College
6:54 AM ET 8-K
Divestiture DTE Energy Co DTE

DTE Energy Divestiture to J.P. Morgan Asset Management for $3B

DTE Energy entered into a definitive agreement to sell its non-utility DTE Vantage business to institutional investors advised by J.P. Morgan Asset Management for approximately $3 billion. The strategic sale allows DTE to focus resources on its regulated electric and gas utilities and support a $44 billion five-year capital investment plan. The transaction is expected to close in the first half of 2027.

Value
$3B
Counterparty
J.P. Morgan Asset Management

“This transaction advances our strategy to focus our resources on our regulated electric and gas utilities, where we see significant opportunities to invest on behalf of customers and communities. The sale supports our plan to deliver meaningful affordability benefits for customers, strengthens our ability to execute a substantial utility investment plan and positions DTE as a high-growth, premium utility with a stronger long-term outlook.”

Joi Harris, DTE president and CEO
6:32 AM ET 8-K
Licensing Deal Evommune, Inc. EVMN

Evommune Licensing Deal with Hinova Pharmaceuticals Inc.

Evommune announced it has entered into an exclusive license agreement with Hinova Pharmaceuticals for EVO570, an oral VAV1-directed molecular glue degrader. Evommune acquired worldwide rights (excluding Greater China) to develop, manufacture, and commercialize the candidate, which it plans to develop for rheumatoid arthritis.

Counterparty
Hinova Pharmaceuticals Inc.
6:06 AM ET 8-K
Nasdaq/NYSE Compliance Notice Cognition Therapeutics Inc CGTX

Cognition Therapeutics Nasdaq/NYSE Compliance Notice

Cognition Therapeutics received a deficiency notice from Nasdaq on November 3, 2026, because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The company has until May 3, 2027, to regain compliance by having its stock price close at or above $1.00 for at least 10 consecutive business days.

Counterparty
Nasdaq
Term
180 days

“The work we conducted with the Office of Neuroscience at the FDA during 2026 culminated in the development of a trial protocol for a planned registrational study of zervimesine (CT1812) in people with dementia with Lewy bodies (DLB). We are now evaluating our plans for manufacturing, site selection, and patient recruitment.”

Lisa Ricciardi, Cognition’s president and CEO

“At the same time, we are working with our collaborators at the Alzheimer’s Clinical Trial Consortium (ACTC) to prepare for the conclusion of the Phase 2 START Study in people with MCI and early Alzheimer’s disease. Top-line results from START are anticipated in the second half of 2027 and will inform our plans for zervimesine in Alzheimer’s disease.”

Lisa Ricciardi, Cognition’s president and CEO
6:05 AM ET 8-K
M&A Deal Vistra Corp. VST

Vistra Signs $2.2B M&A Deal with Q-Generation Holdings, LLC

Vistra Corp. completed its acquisition of Cogentrix Energy from funds managed by Quantum Capital Group for approximately $2.2 billion in cash and 5 million shares of common stock. The deal adds 10 natural gas generation facilities totaling approximately 5,500 MW of capacity across the PJM, ISO-NE, and ERCOT markets, bringing Vistra's total generation portfolio to nearly 50,000 MW.

Value
$2.2B
Counterparty
Q-Generation Holdings, LLC

“Natural gas plays a critical role in meeting our nation’s growing energy needs, and the Cogentrix assets are a strong strategic fit for Vistra as we continue to grow our generation portfolio. We’re excited to bring these experienced teams together around a shared commitment to safety, operational excellence, and reliability. Our Vistra team knows how to successfully integrate generation assets into our fleet, and we look forward to building on Cogentrix’s strengths and delivering long-term value for our stakeholders.”

Jim Burke, president and chief executive officer of Vistra
6:04 AM ET 8-K
Regulatory Approval Bioxytran, Inc BIXT

Bioxytran Regulatory Approval

Bioxytran secured a government-issued Free Sale Certificate for its A-SUQAR chewable nutraceutical, a key regulatory milestone for market entry in the UAE and Gulf Cooperation Council region. The certification confirms the product is lawfully manufactured and sold as a health supplement, allowing the company to proceed with product registration in markets with high diabetes prevalence.

6:01 AM ET 8-K
Nasdaq/NYSE Compliance Notice Intrusion Inc INTZ

Intrusion Nasdaq/NYSE Compliance Notice

Intrusion Inc. received a formal notification from Nasdaq granting an additional 180-day extension, until May 3, 2027, to regain compliance with the $1.00 minimum bid price requirement. The company failed to regain compliance during the initial 180-day period and has indicated it may implement a reverse stock split if necessary to cure the deficiency. The common stock will continue to trade on the Nasdaq Capital Market under the symbol 'INTZ' during this second compliance period.

Counterparty
Nasdaq
Term
until May 3, 2027
6:05 PM ET
Earnings Call Dhi Group, Inc. DHX ▶ Call

DHI Group Earnings Call: Key Takeaways

DHI Group shows a tale of two segments: ClearanceJobs is thriving with 18% revenue growth, while Dice faces continued enterprise renewal pressure despite narrowing booking declines.

Call
Nov 4, 2026, 5:00 PM ET
5:47 PM ET
Earnings Call Lyntris Inc. LYNX ▶ Call

Lyntris Earnings Call: Key Takeaways

Lyntris Inc. delivered record revenue and strong cash flow, though margins faced compression due to early-stage design and development work on major defense programs.

Call
Nov 4, 2026, 4:30 PM ET
5:31 PM ET 8-K
M&A Deal Medicus Pharma Ltd. MDCX

Medicus Pharma Announces $135M M&A Deal

Medicus Pharma announced that its wholly-owned subsidiary, SkinJect, Inc., has entered into a non-binding letter of intent for a business combination with an undisclosed SPAC. The proposed transaction contemplates a $135 million pre-money enterprise valuation for SkinJect and is expected to close in the first half of 2027, with Medicus seeking to retain majority ownership.

Value
$135M

“We believe this proposed transaction will represent a meaningful step toward executing our strategic mandate to unlock the value of this important clinical-stage asset for our shareholders. The proposed transaction, in addition to establishing an independent public-market platform and access for Skinject, will also allow Medicus to participate in its future growth”

Dr. Raza Bokhari, Medicus Exec. Chairman and CEO
5:29 PM ET 8-K
M&A Deal cbdMD, Inc. YCBD

cbdMD M&A Deal with Twinlab Consolidated Holdings, Inc.

cbdMD, Inc. completed the acquisition of the operating assets and brands of Twinlab Consolidated Holdings, including the Twinlab, Reserveage, and Metabolife brands, through a Florida assignment for the benefit of creditors proceeding. The consideration included the assumption of senior secured debt and the issuance of approximately 2.23 million shares of common stock to the secured creditor. The deal diversifies cbdMD's portfolio beyond hemp-derived products into the broader nutritional supplement and wellness market.

Counterparty
Twinlab Consolidated Holdings, Inc.
5:29 PM ET 8-K
Nasdaq/NYSE Compliance Notice Bio Green Med Solution, Inc. BGMS

Bio Green Med Solution Nasdaq/NYSE Compliance Notice

Bio Green Med Solution received a deficiency notice from Nasdaq on October 29, 2026, because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. The company has until April 27, 2027, to regain compliance and is considering a reverse stock split as a potential remedy in connection with its pending business combination with Future NRG Sdn. Bhd.

Counterparty
Nasdaq Stock Market LLC
Term
180 days
5:26 PM ET 8-K
Capital Raise Quoin Pharmaceuticals Ltd. QNRX

Quoin Pharmaceuticals Capital Raise

Quoin Pharmaceuticals entered into an at-the-market (ATM) sales agreement with Leerink Partners LLC to sell American Depositary Shares (ADSs) from time to time. Leerink Partners will act as the sales agent and receive a 3.0% commission on gross proceeds from any sales made under the program.

Counterparty
Leerink Partners LLC
5:23 PM ET 8-K
Capital Raise Summit Therapeutics Inc. SMMT

Summit Therapeutics Capital Raise

Summit Therapeutics Inc. filed a prospectus supplement to its automatic shelf registration statement on Form S-3 for the potential issuance of common stock. The filing includes a legal opinion from Baker & Hostetler LLP regarding the legality of the shares being offered.

5:21 PM ET 8-K
M&A Deal Star Equity Holdings, Inc. STRR

Star Equity Holdings Signs $2.5M M&A Deal with Cornerstone RPO, LLC

Star Equity Holdings, through its subsidiary Hudson Talent Solutions, acquired the assets of recruitment process outsourcing provider Cornerstone RPO for up to $2.5 million in total consideration. The deal includes $0.5 million in upfront cash, $0.25 million in deferred notes, and up to $1.75 million in contingent earnout and contract-transfer payments. The acquisition expands the company's U.S. recruitment footprint and adds established enterprise client relationships across North America.

Value
$2.5M
Counterparty
Cornerstone RPO, LLC
5:18 PM ET 8-K
Capital Raise Mgt Capital Investments, Inc. MGTI

Mgt Capital Investments Capital Raise

MGT Capital Investments entered into securities purchase agreements for a private placement of up to $225,000 of common stock. As of the filing date, the company has closed on $100,000 in gross proceeds from two accredited investors at a price of $0.001 per share. The funds are intended for general working capital purposes.

Term
through Dec 2026
5:15 PM ET 8-K
Nasdaq/NYSE Compliance Notice Cayson Acquisition Corp CAPN

Cayson Acquisition Nasdaq/NYSE Compliance Notice

Cayson Acquisition Corp received a notice from Nasdaq on October 29, 2026, indicating that the company failed to regain compliance with the Minimum Total Holders Rule (Listing Rule 5450(a)(2)) during its extension period. Consequently, Nasdaq has initiated delisting procedures for the company's securities. The company has appealed the determination to maintain its listing while it works to provide documentation establishing the required 400 total holders.

Counterparty
Nasdaq
5:13 PM ET 8-K
Capital Raise WEC Energy Group, Inc. WEC

WEC Energy Group Capital Raise

WEC Energy Group entered into an equity distribution agreement to establish an at-the-market (ATM) offering program for up to $4.0 billion of its common stock. The program includes provisions for forward sale agreements with various financial institutions acting as sales agents and forward purchasers.

5:11 PM ET 8-K
Licensing Deal Evommune, Inc. EVMN

Evommune Licensing Deal with Hinova Pharmaceuticals Inc. Worth $30M

Evommune has entered into an exclusive license agreement with Hinova Pharmaceuticals to develop and commercialize EVO570, a VAV1 molecular glue degrader, globally excluding Greater China. Evommune will pay $20 million upfront in cash and $10 million in pre-funded warrants, with Hinova eligible for up to $1.07 billion in additional milestone payments plus tiered royalties.

Value
$30M
Counterparty
Hinova Pharmaceuticals Inc.
Term
Royalty Term

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.